omapatrilat

Known as: octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo-7H-pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, Omapatrilate, (4S,7S,10aS)-Octahydro-4-((S)-Alpha-Mercaptohydrocinnamamido)-5-Oxo-7H-Pyrido(2,1-B)(1,3)Thiazepine-7-Carboxylic Acid 
A vasopeptidase inhibitor with antihypertensive activity. Omapatrilat exerts its effect by inhibiting angiotensin converting enzyme (ACE) and neutral… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
BACKGROUND Recent reports suggest that existing antihypertensive agents may not have sufficient efficacy to control blood… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Increased pulse pressure, an indicator of conduit vessel stiffness, is a strong independent predictor of… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2002
2002
The contribution of angiotensin-(1-7) [Ang-(1-7)] to the antihypertensive actions of omapatrilat, a novel vasopeptidase inhibitor… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2002
2002
At the American College of Cardiology in March two major trials were presented. The publicity surrounding the two could not have… (More)
Is this relevant?
Review
2001
Review
2001
Bristol-Myers Squibb (BMS) is developing the vasopeptidase inihibitor, omapatrilat, a dual inhibitor of angiotensin converting… (More)
Is this relevant?
2001
2001
Omapatrilat, a vasopeptidase inhibitor, simultaneously inhibits neutral endopeptidase and ACE. The efficacy and hormonal profile… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND We aimed to assess in patients with congestive heart failure whether dual inhibition of neutral endopeptidase and… (More)
Is this relevant?
1999
1999
Vasopeptidase inhibitors are single molecules that inhibit neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Combined inhibition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) produces cardiovascular effects… (More)
Is this relevant?